Mesa Laboratories Inc's revenue was $249m in fiscal 2026, up 3.4% on the year before. Since fiscal 2011 ($34.2m) it has grown at a compound 14.1% a year. Over the last twelve months it was $250m.
Revenue history
US$ millions unless shown otherwise.
Fiscal years, plus the last twelve months (LTM) when newer.
Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.
Where the revenue comes from
Fiscal year to March 31, 2026
Sterilization and Disinfection Control$102M
Calibration Solutions$53.6M
Biopharmaceutical Development$48.6M
Clinical Genomics$45.4M
Segments
Line of business
Revenue
Share
YoY
Sterilization and Disinfection Control
$102M
40.8%
▲ 8.7%
Calibration Solutions
$53.6M
21.5%
▲ 3.5%
Biopharmaceutical Development
$48.6M
19.5%
▼ 0.2%
Clinical Genomics
$45.4M
18.2%
▼ 3.6%
Products$203M
Services$45.7M
Products and services
Line of business
Revenue
Share
YoY
Products
$203M
81.6%
▲ 2.5%
Services
$45.7M
18.4%
▲ 7.4%
United States$117M
Other$112M
China$20.4M
Geography
Region
Revenue
Share
YoY
United States
$117M
46.9%
▲ 0.2%
Other
$112M
44.9%
▲ 12.9%
China
$20.4M
8.2%
▼ 19.2%
From Mesa Laboratories Inc's 10-K filed June 3, 2026, as tagged in the filing.
View filing. Indented rows are part of the
line above; their share is of that line. In the bars, the
faint bar behind is the year before.
Revenue against peers
Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.
